UY30137A1 - Monohidrato de rimonabant, su procedimiento de preparación y composiciones farmacéuticas que lo contienen - Google Patents

Monohidrato de rimonabant, su procedimiento de preparación y composiciones farmacéuticas que lo contienen

Info

Publication number
UY30137A1
UY30137A1 UY30137A UY30137A UY30137A1 UY 30137 A1 UY30137 A1 UY 30137A1 UY 30137 A UY30137 A UY 30137A UY 30137 A UY30137 A UY 30137A UY 30137 A1 UY30137 A1 UY 30137A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical compositions
rimonabant
compositions containing
monohidrate
preparation procedure
Prior art date
Application number
UY30137A
Other languages
English (en)
Inventor
Ochsenbein Philippe
Duplaa Helenc
Fours Baptiste
Coquerel Gerard
Monnier Olivier
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37075667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30137(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY30137A1 publication Critical patent/UY30137A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención tiene por objeto monohidrato de rimonabant, su procedimiento de preparación y las composiciones farmacéuticas que lo contienen.
UY30137A 2006-02-08 2007-02-08 Monohidrato de rimonabant, su procedimiento de preparación y composiciones farmacéuticas que lo contienen UY30137A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0601253A FR2897060B1 (fr) 2006-02-08 2006-02-08 Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
UY30137A1 true UY30137A1 (es) 2007-09-28

Family

ID=37075667

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30137A UY30137A1 (es) 2006-02-08 2007-02-08 Monohidrato de rimonabant, su procedimiento de preparación y composiciones farmacéuticas que lo contienen

Country Status (20)

Country Link
US (1) US20090048449A1 (es)
EP (1) EP1984341A1 (es)
JP (1) JP2009526025A (es)
KR (1) KR20080093042A (es)
CN (1) CN101405271A (es)
AR (1) AR059327A1 (es)
AU (1) AU2007213649A1 (es)
BR (1) BRPI0707711A2 (es)
CA (1) CA2641494A1 (es)
DO (1) DOP2007000023A (es)
EA (1) EA200870236A1 (es)
FR (1) FR2897060B1 (es)
GT (1) GT200700014A (es)
IL (1) IL192963A0 (es)
MA (1) MA30312B1 (es)
NO (1) NO20083521L (es)
TW (1) TW200804343A (es)
UY (1) UY30137A1 (es)
WO (1) WO2007090949A1 (es)
ZA (1) ZA200806713B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008026219A2 (en) * 2006-09-01 2008-03-06 Hetero Drugs Limited Novel polymorphs of rimonabant
WO2008056377A2 (en) * 2006-11-06 2008-05-15 Cadila Healthcare Limited Polymorphic forms of rimonabant
CA2970192C (en) * 2014-12-08 2020-08-04 Crystal Pharmatech Co., Ltd. Crystalline forms of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
JP4746931B2 (ja) * 2005-07-22 2011-08-10 株式会社日立製作所 フラットディスプレイパネルモジュール及びフラットディスプレイ装置
WO2008026219A2 (en) * 2006-09-01 2008-03-06 Hetero Drugs Limited Novel polymorphs of rimonabant
WO2008035023A1 (en) * 2006-09-19 2008-03-27 Cipla Limited Polymorphs of rimonabant

Also Published As

Publication number Publication date
EA200870236A1 (ru) 2009-02-27
AR059327A1 (es) 2008-03-26
CN101405271A (zh) 2009-04-08
KR20080093042A (ko) 2008-10-17
WO2007090949A1 (fr) 2007-08-16
GT200700014A (es) 2007-09-19
BRPI0707711A2 (pt) 2011-05-10
FR2897060B1 (fr) 2008-07-25
AU2007213649A1 (en) 2007-08-16
IL192963A0 (en) 2009-02-11
NO20083521L (no) 2008-10-24
DOP2007000023A (es) 2008-02-15
EP1984341A1 (fr) 2008-10-29
US20090048449A1 (en) 2009-02-19
MA30312B1 (fr) 2009-04-01
FR2897060A1 (fr) 2007-08-10
JP2009526025A (ja) 2009-07-16
TW200804343A (en) 2008-01-16
ZA200806713B (en) 2009-10-28
CA2641494A1 (fr) 2007-08-16

Similar Documents

Publication Publication Date Title
HN2009000566A (es) Nuevos derivados de diosmetina, su procedimiento de prearacion y las composiciones farmaceuticas que lo contienen.
EA201170772A1 (ru) Органические соединения
NO20084334L (no) Farmasoytiske sammensetninger
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
NO20090295L (no) Substituerte heteroarylderivater
CL2012002771A1 (es) Compuestos derivados de ariletinilo sustituidos, moduladores de los receptores mglur5; proceso de obtencion; composicion farmaceutica; y su uso en el tratamiento o prevencion de la esquizofrenia, enfermedades cognitivas, sindrome de x fragil o el autismo.
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
TW200716525A (en) Process for preparation of sulfamide derivatives
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
ECSP066373A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
EA201170832A1 (ru) Пуриновые соединения
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
CR10673A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
PA8792401A1 (es) Fenilendiaminas
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.
UY29631A1 (es) Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica
UY30137A1 (es) Monohidrato de rimonabant, su procedimiento de preparación y composiciones farmacéuticas que lo contienen

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20130118